Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial
Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizum...
Uloženo v:
| Vydáno v: | Pediatrics (Evanston) Ročník 125; číslo 1; s. e35 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.01.2010
|
| Témata: | |
| ISSN: | 1098-4275, 1098-4275 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab.
This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <or=6 months at enrollment or children aged <or=24 months with chronic lung disease of prematurity who received 15 mg/kg palivizumab or motavizumab monthly. Secondary end points included outpatient medically attended lower respiratory tract infections (MALRIs), RSV-specific LRIs, otitis media, antibiotic use, development of antimotavizumab antibodies, and motavizumab serum concentrations.
Motavizumab recipients had a 26% relative reduction in RSV hospitalization compared with palivizumab recipients, achieving noninferiority. Motavizumab was superior to palivizumab for reduction of RSV-specific outpatient MALRIs (50% relative reduction). Overall, adverse events (AEs) were not significantly different between groups. Cutaneous events were reported in 2 percentage points more motavizumab recipients (7.2% vs 5.1%); most were mild, but 0.3% resulted in dosing discontinuation. Antidrug antibodies (ADA) were detected in 1.8% of motavizumab recipients. Patients with anti-drug antibody reported 6 RSV events and 17 cutaneous events.
Children receiving prophylaxis with motavizumab or palivizumab had low rates of RSV hospitalization; motavizumab recipients experienced 50% fewer RSV MALRIs than palivizumab recipients. AEs were similar in both groups, although cutaneous AEs were higher for motavizumab recipients. Motavizumab may offer an improved alternative in prophylaxis for serious RSV disease in infants and children at high risk. |
|---|---|
| AbstractList | Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab.OBJECTIVEPalivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab.This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <or=6 months at enrollment or children aged <or=24 months with chronic lung disease of prematurity who received 15 mg/kg palivizumab or motavizumab monthly. Secondary end points included outpatient medically attended lower respiratory tract infections (MALRIs), RSV-specific LRIs, otitis media, antibiotic use, development of antimotavizumab antibodies, and motavizumab serum concentrations.METHODSThis randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <or=6 months at enrollment or children aged <or=24 months with chronic lung disease of prematurity who received 15 mg/kg palivizumab or motavizumab monthly. Secondary end points included outpatient medically attended lower respiratory tract infections (MALRIs), RSV-specific LRIs, otitis media, antibiotic use, development of antimotavizumab antibodies, and motavizumab serum concentrations.Motavizumab recipients had a 26% relative reduction in RSV hospitalization compared with palivizumab recipients, achieving noninferiority. Motavizumab was superior to palivizumab for reduction of RSV-specific outpatient MALRIs (50% relative reduction). Overall, adverse events (AEs) were not significantly different between groups. Cutaneous events were reported in 2 percentage points more motavizumab recipients (7.2% vs 5.1%); most were mild, but 0.3% resulted in dosing discontinuation. Antidrug antibodies (ADA) were detected in 1.8% of motavizumab recipients. Patients with anti-drug antibody reported 6 RSV events and 17 cutaneous events.RESULTSMotavizumab recipients had a 26% relative reduction in RSV hospitalization compared with palivizumab recipients, achieving noninferiority. Motavizumab was superior to palivizumab for reduction of RSV-specific outpatient MALRIs (50% relative reduction). Overall, adverse events (AEs) were not significantly different between groups. Cutaneous events were reported in 2 percentage points more motavizumab recipients (7.2% vs 5.1%); most were mild, but 0.3% resulted in dosing discontinuation. Antidrug antibodies (ADA) were detected in 1.8% of motavizumab recipients. Patients with anti-drug antibody reported 6 RSV events and 17 cutaneous events.Children receiving prophylaxis with motavizumab or palivizumab had low rates of RSV hospitalization; motavizumab recipients experienced 50% fewer RSV MALRIs than palivizumab recipients. AEs were similar in both groups, although cutaneous AEs were higher for motavizumab recipients. Motavizumab may offer an improved alternative in prophylaxis for serious RSV disease in infants and children at high risk.CONCLUSIONSChildren receiving prophylaxis with motavizumab or palivizumab had low rates of RSV hospitalization; motavizumab recipients experienced 50% fewer RSV MALRIs than palivizumab recipients. AEs were similar in both groups, although cutaneous AEs were higher for motavizumab recipients. Motavizumab may offer an improved alternative in prophylaxis for serious RSV disease in infants and children at high risk. Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab. This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <or=6 months at enrollment or children aged <or=24 months with chronic lung disease of prematurity who received 15 mg/kg palivizumab or motavizumab monthly. Secondary end points included outpatient medically attended lower respiratory tract infections (MALRIs), RSV-specific LRIs, otitis media, antibiotic use, development of antimotavizumab antibodies, and motavizumab serum concentrations. Motavizumab recipients had a 26% relative reduction in RSV hospitalization compared with palivizumab recipients, achieving noninferiority. Motavizumab was superior to palivizumab for reduction of RSV-specific outpatient MALRIs (50% relative reduction). Overall, adverse events (AEs) were not significantly different between groups. Cutaneous events were reported in 2 percentage points more motavizumab recipients (7.2% vs 5.1%); most were mild, but 0.3% resulted in dosing discontinuation. Antidrug antibodies (ADA) were detected in 1.8% of motavizumab recipients. Patients with anti-drug antibody reported 6 RSV events and 17 cutaneous events. Children receiving prophylaxis with motavizumab or palivizumab had low rates of RSV hospitalization; motavizumab recipients experienced 50% fewer RSV MALRIs than palivizumab recipients. AEs were similar in both groups, although cutaneous AEs were higher for motavizumab recipients. Motavizumab may offer an improved alternative in prophylaxis for serious RSV disease in infants and children at high risk. |
| Author | Dagan, Ron Losonsky, Genevieve A Hall, Caroline B Connor, Edward M Simões, Eric A F Carbonell-Estrany, Xavier Harris, Brian Hultquist, Micki |
| Author_xml | – sequence: 1 givenname: Xavier surname: Carbonell-Estrany fullname: Carbonell-Estrany, Xavier email: xcarbo@clinic.ub.es organization: Neonatology Service, Hospital Clínic, Agrupació Sanitèria Clínic, Hospital de Sant Joan de Déu, Barcelona, Spain. xcarbo@clinic.ub.es – sequence: 2 givenname: Eric A F surname: Simões fullname: Simões, Eric A F – sequence: 3 givenname: Ron surname: Dagan fullname: Dagan, Ron – sequence: 4 givenname: Caroline B surname: Hall fullname: Hall, Caroline B – sequence: 5 givenname: Brian surname: Harris fullname: Harris, Brian – sequence: 6 givenname: Micki surname: Hultquist fullname: Hultquist, Micki – sequence: 7 givenname: Edward M surname: Connor fullname: Connor, Edward M – sequence: 8 givenname: Genevieve A surname: Losonsky fullname: Losonsky, Genevieve A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20008423$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1LxDAQxYOsuB969Si5eeqapG3S9SaLX7DiRc8lTSY22jY1SRfrX2_BFTzNg3m_4c1bolnnOkDonJI1zTN21YMOa0ZIkVCS8iO0oGRTJBkT-eyfnqNlCO-EkCwX7ATNJ4AUGUsXqH5yUe7t99DKChvnce9dX4-N_LIBO4M9hN56GZ0fcRg7NUYrG7y3fgjYdri2b3XibfjAqraN9tBdY4mnjLYz4K3zNo44-ok5RcdGNgHODnOFXu9uX7YPye75_nF7s0tUyklMIGeKT8mo1sBByMoIngNVSnO6YbLKNtoIPS0IJSLVjGstTVEYs6mAVcKwFbr8vTs98jlAiGVrg4KmkR24IZQizRijGSWT8-LgHKoWdNl720o_ln_lsB_vXWv1 |
| CitedBy_id | crossref_primary_10_1891_NN_2023_0056 crossref_primary_10_1056_NEJMoa2026920 crossref_primary_10_1097_INF_0000000000003121 crossref_primary_10_1007_s12325_010_0100_z crossref_primary_10_4155_fmc_10_235 crossref_primary_10_1128_microbiolspec_AID_0014_2014 crossref_primary_10_1097_INF_0000000000000813 crossref_primary_10_3109_14767058_2013_831282 crossref_primary_10_1186_1471_2431_12_147 crossref_primary_10_5409_wjcp_v1_i3_8 crossref_primary_10_1080_14760584_2017_1333425 crossref_primary_10_3390_ijms18030556 crossref_primary_10_3390_vaccines11121797 crossref_primary_10_1002_ebch_1950 crossref_primary_10_3390_v12060637 crossref_primary_10_1097_INF_0000000000001916 crossref_primary_10_3390_biomedicines10081861 crossref_primary_10_1016_j_addr_2020_12_004 crossref_primary_10_1542_peds_2014_1666 crossref_primary_10_1007_s40121_014_0033_y crossref_primary_10_1016_j_jinf_2013_09_021 crossref_primary_10_1080_17476348_2018_1401926 crossref_primary_10_3389_fimmu_2023_1206026 crossref_primary_10_1111_ped_70021 crossref_primary_10_1016_j_vaccine_2016_09_026 crossref_primary_10_1146_annurev_immunol_042718_041309 crossref_primary_10_1016_j_antiviral_2014_12_009 crossref_primary_10_1136_bmjopen_2011_000156 crossref_primary_10_1371_journal_pone_0050852 crossref_primary_10_1186_s10020_020_00162_6 crossref_primary_10_1001_jamanetworkopen_2023_0023 crossref_primary_10_1016_j_vaccine_2017_05_045 crossref_primary_10_1586_14760584_2013_824706 crossref_primary_10_1097_INF_0b013e318218ab9e crossref_primary_10_1586_14760584_2016_1114418 crossref_primary_10_1038_s43856_025_00807_9 crossref_primary_10_1186_1471_2431_10_38 crossref_primary_10_1016_j_virusres_2011_09_020 crossref_primary_10_1016_j_jconrel_2020_11_057 crossref_primary_10_1038_s41385_019_0243_4 crossref_primary_10_1097_INF_0000000000000240 crossref_primary_10_1002_14651858_CD016224 crossref_primary_10_1182_blood_2010_08_263400 crossref_primary_10_2217_fvl_14_60 crossref_primary_10_1016_j_jinf_2015_04_025 crossref_primary_10_1007_s40259_023_00596_4 crossref_primary_10_1186_s13643_020_01527_y crossref_primary_10_1080_14656566_2023_2213433 crossref_primary_10_1002_ppul_23561 crossref_primary_10_3390_molecules27072263 crossref_primary_10_1177_1753465811402534 crossref_primary_10_1186_s13643_019_1251_x crossref_primary_10_1007_s40272_023_00606_6 crossref_primary_10_1016_S1473_3099_15_00247_9 crossref_primary_10_1016_j_cct_2012_07_010 crossref_primary_10_3390_vaccines8040558 crossref_primary_10_1093_jpids_piae027 crossref_primary_10_1007_s40121_020_00383_6 crossref_primary_10_1016_j_coph_2013_04_010 crossref_primary_10_1016_j_imlet_2019_06_009 crossref_primary_10_1016_j_jped_2022_10_004 crossref_primary_10_1080_14787210_2025_2481908 crossref_primary_10_1002_mco2_70016 crossref_primary_10_1016_j_ccell_2012_07_008 crossref_primary_10_3390_ijms22073703 crossref_primary_10_1093_infdis_jiq100 crossref_primary_10_1038_s41372_020_0689_y crossref_primary_10_1093_infdis_jiu307 crossref_primary_10_1016_j_cell_2021_05_005 crossref_primary_10_1089_hum_2021_079 crossref_primary_10_1586_eri_10_140 crossref_primary_10_1016_j_antiviral_2023_105791 crossref_primary_10_1016_j_tim_2017_09_009 crossref_primary_10_1093_infdis_jiu828 crossref_primary_10_3390_v5010087 crossref_primary_10_1128_AAC_00567_12 crossref_primary_10_1080_14787210_2024_2403147 crossref_primary_10_1093_jac_dkad076 crossref_primary_10_1002_ppul_21395 crossref_primary_10_1371_journal_pone_0289828 crossref_primary_10_3390_vaccines8040672 crossref_primary_10_1016_j_vaccine_2014_09_030 crossref_primary_10_1128_JVI_01568_17 crossref_primary_10_1007_s40121_014_0042_x crossref_primary_10_1016_j_vaccine_2012_11_009 crossref_primary_10_1080_14787210_2018_1543589 crossref_primary_10_1111_bcp_13280 crossref_primary_10_1038_s41573_022_00495_3 crossref_primary_10_1002_rmv_2576 crossref_primary_10_1126_scitranslmed_aax2466 crossref_primary_10_1002_advs_202306729 crossref_primary_10_1056_NEJMoa1913556 crossref_primary_10_1016_j_pop_2011_07_006 crossref_primary_10_2147_IDR_S379660 crossref_primary_10_1016_j_jaci_2017_07_001 crossref_primary_10_1186_1471_2458_11_S3_S30 crossref_primary_10_1016_j_antiviral_2023_105783 crossref_primary_10_1093_infdis_jiv406 crossref_primary_10_1080_14787210_2017_1279970 crossref_primary_10_1002_sim_5312 crossref_primary_10_1186_s12879_014_0544_x crossref_primary_10_1016_j_iac_2019_03_005 crossref_primary_10_1016_S2213_2600_15_00255_6 crossref_primary_10_1016_j_bbmt_2012_12_019 crossref_primary_10_7759_cureus_69640 crossref_primary_10_1093_cid_cir531 crossref_primary_10_1203_PDR_0b013e318220a553 crossref_primary_10_3928_19382359_20180816_01 crossref_primary_10_1097_INF_0b013e31826366e3 crossref_primary_10_3390_vaccines9090961 crossref_primary_10_1111_bjh_14595 crossref_primary_10_1007_s12325_010_0101_y crossref_primary_10_1007_s41061_017_0129_4 crossref_primary_10_1111_eip_13501 crossref_primary_10_1517_13543784_2015_1099626 crossref_primary_10_1080_14656566_2017_1322063 crossref_primary_10_3390_pathogens12020154 crossref_primary_10_1016_S1473_3099_15_00304_7 crossref_primary_10_1093_infdis_jit512 crossref_primary_10_1080_21645515_2021_1883379 crossref_primary_10_2217_imt_10_53 crossref_primary_10_1007_s12519_015_0055_x crossref_primary_10_1111_irv_12173 crossref_primary_10_1007_s40121_014_0046_6 crossref_primary_10_1002_rmv_1717 crossref_primary_10_1002_14651858_CD013757_pub2 crossref_primary_10_1002_14651858_CD013757_pub3 crossref_primary_10_1055_a_1990_2633 crossref_primary_10_3390_pathogens13060503 crossref_primary_10_1093_infdis_jiy026 crossref_primary_10_1128_JVI_00493_13 crossref_primary_10_1016_j_prrv_2012_12_006 crossref_primary_10_3851_IMP1873 crossref_primary_10_1080_21645515_2017_1337614 crossref_primary_10_1093_infdis_jiw483 crossref_primary_10_1016_j_nbt_2025_05_007 crossref_primary_10_1007_s40121_018_0188_z crossref_primary_10_1002_ppul_27041 crossref_primary_10_1016_j_jim_2019_04_003 crossref_primary_10_1038_s41541_017_0019_3 crossref_primary_10_1080_14656566_2020_1806821 crossref_primary_10_1097_INF_0b013e3182184ae7 |
| ContentType | Journal Article |
| Contributor | Dort, J Podesvova, H Gire, C Honomichlova, H Hein, N Szyld, E Ghenev, E Lenclen, R Singh, A Escande, B Cintra, O Berezin, E Horneff, G Salzer, H Berger, A Sarlangue, J Graña, M da Cunha, C Dirdal, M Poeschl, Mainz J Rascher, W Rosmanova, R Stranak, Z Biolek, J Chambery, C H Stein, R Nedkova, V Araujo, O Pirmin, H Glorieux, I Roberton, D Cihar, M Saliba, E Dachev, S Rieger, C Le Bouedec, S Boucher, F Paes, B Harms, K Kacet, N Albertsen, P Macko, J Roze, J-C Peña, V Mitchell, I Berner, R Ilieva, V Hristova, E de la Pintiere, A Janota, J Blayney, M Slancheva, B Liese, J Ferrero, F Lima, M Picaud, J Leke, A Sterniste, W Möller, O Chiu, A Kattner, E Hui, C Galabov, I Nørgaard-Hansen, K Filho, N Bigsby, K Valerius, N Georgieva, A Plavka, R McDonald, J Resch, B Lebel, M Kokstein, Z Robinson, J Semama, D Novoa, J Hanzl, M Abarca, K Krasteva, M Mena, P Robertson, C Tan, B Nissen, M Carmichael, A Kantor, L Wake, C Pinquier, D Walther, M Vivanco, G Guillermet, C Lieser, U McCreanor, J Rech, A Lindemann, C Vain, N Zach, J Langley, J Bacheyie, G Fernandez, P Wilson, A |
| Contributor_xml | – sequence: 1 givenname: F surname: Ferrero fullname: Ferrero, F – sequence: 2 givenname: M surname: Graña fullname: Graña, M – sequence: 3 givenname: E surname: Szyld fullname: Szyld, E – sequence: 4 givenname: N surname: Vain fullname: Vain, N – sequence: 5 givenname: A surname: Carmichael fullname: Carmichael, A – sequence: 6 givenname: J surname: McCreanor fullname: McCreanor, J – sequence: 7 givenname: M surname: Nissen fullname: Nissen, M – sequence: 8 givenname: D surname: Roberton fullname: Roberton, D – sequence: 9 givenname: C surname: Robertson fullname: Robertson, C – sequence: 10 givenname: C surname: Wake fullname: Wake, C – sequence: 11 givenname: A surname: Wilson fullname: Wilson, A – sequence: 12 givenname: A surname: Berger fullname: Berger, A – sequence: 13 givenname: B surname: Resch fullname: Resch, B – sequence: 14 givenname: H surname: Salzer fullname: Salzer, H – sequence: 15 givenname: W surname: Sterniste fullname: Sterniste, W – sequence: 16 givenname: O surname: Araujo fullname: Araujo, O – sequence: 17 givenname: E surname: Berezin fullname: Berezin, E – sequence: 18 givenname: O surname: Cintra fullname: Cintra, O – sequence: 19 givenname: C surname: da Cunha fullname: da Cunha, C – sequence: 20 givenname: N surname: Filho fullname: Filho, N – sequence: 21 givenname: N surname: Hein fullname: Hein, N – sequence: 22 givenname: M surname: Lima fullname: Lima, M – sequence: 23 givenname: R surname: Stein fullname: Stein, R – sequence: 24 givenname: S surname: Dachev fullname: Dachev, S – sequence: 25 givenname: I surname: Galabov fullname: Galabov, I – sequence: 26 givenname: A surname: Georgieva fullname: Georgieva, A – sequence: 27 givenname: E surname: Ghenev fullname: Ghenev, E – sequence: 28 givenname: E surname: Hristova fullname: Hristova, E – sequence: 29 givenname: V surname: Ilieva fullname: Ilieva, V – sequence: 30 givenname: M surname: Krasteva fullname: Krasteva, M – sequence: 31 givenname: V surname: Nedkova fullname: Nedkova, V – sequence: 32 givenname: R surname: Rosmanova fullname: Rosmanova, R – sequence: 33 givenname: B surname: Slancheva fullname: Slancheva, B – sequence: 34 givenname: G surname: Bacheyie fullname: Bacheyie, G – sequence: 35 givenname: K surname: Bigsby fullname: Bigsby, K – sequence: 36 givenname: M surname: Blayney fullname: Blayney, M – sequence: 37 givenname: F surname: Boucher fullname: Boucher, F – sequence: 38 givenname: A surname: Chiu fullname: Chiu, A – sequence: 39 givenname: C surname: Hui fullname: Hui, C – sequence: 40 givenname: J surname: Langley fullname: Langley, J – sequence: 41 givenname: M surname: Lebel fullname: Lebel, M – sequence: 42 givenname: J surname: McDonald fullname: McDonald, J – sequence: 43 givenname: I surname: Mitchell fullname: Mitchell, I – sequence: 44 givenname: B surname: Paes fullname: Paes, B – sequence: 45 givenname: J surname: Robinson fullname: Robinson, J – sequence: 46 givenname: A surname: Singh fullname: Singh, A – sequence: 47 givenname: B surname: Tan fullname: Tan, B – sequence: 48 givenname: K surname: Abarca fullname: Abarca, K – sequence: 49 givenname: P surname: Fernandez fullname: Fernandez, P – sequence: 50 givenname: C surname: Lindemann fullname: Lindemann, C – sequence: 51 givenname: P surname: Mena fullname: Mena, P – sequence: 52 givenname: J surname: Novoa fullname: Novoa, J – sequence: 53 givenname: V surname: Peña fullname: Peña, V – sequence: 54 givenname: G surname: Vivanco fullname: Vivanco, G – sequence: 55 givenname: J surname: Biolek fullname: Biolek, J – sequence: 56 givenname: M surname: Cihar fullname: Cihar, M – sequence: 57 givenname: J surname: Dort fullname: Dort, J – sequence: 58 givenname: M surname: Hanzl fullname: Hanzl, M – sequence: 59 givenname: H surname: Honomichlova fullname: Honomichlova, H – sequence: 60 givenname: J surname: Janota fullname: Janota, J – sequence: 61 givenname: L surname: Kantor fullname: Kantor, L – sequence: 62 givenname: Z surname: Kokstein fullname: Kokstein, Z – sequence: 63 givenname: J surname: Macko fullname: Macko, J – sequence: 64 givenname: H surname: Podesvova fullname: Podesvova, H – sequence: 65 givenname: R surname: Plavka fullname: Plavka, R – sequence: 66 givenname: Z surname: Stranak fullname: Stranak, Z – sequence: 67 givenname: J surname: Zach fullname: Zach, J – sequence: 68 givenname: P surname: Albertsen fullname: Albertsen, P – sequence: 69 givenname: M surname: Dirdal fullname: Dirdal, M – sequence: 70 givenname: K surname: Nørgaard-Hansen fullname: Nørgaard-Hansen, K – sequence: 71 givenname: N surname: Valerius fullname: Valerius, N – sequence: 72 givenname: A surname: de la Pintiere fullname: de la Pintiere, A – sequence: 73 givenname: B surname: Escande fullname: Escande, B – sequence: 74 givenname: C surname: Gire fullname: Gire, C – sequence: 75 givenname: I surname: Glorieux fullname: Glorieux, I – sequence: 76 givenname: C surname: Guillermet fullname: Guillermet, C – sequence: 77 givenname: N surname: Kacet fullname: Kacet, N – sequence: 78 givenname: S surname: Le Bouedec fullname: Le Bouedec, S – sequence: 79 givenname: A surname: Leke fullname: Leke, A – sequence: 80 givenname: R surname: Lenclen fullname: Lenclen, R – sequence: 81 givenname: J surname: Picaud fullname: Picaud, J – sequence: 82 givenname: D surname: Pinquier fullname: Pinquier, D – sequence: 83 givenname: J-C surname: Roze fullname: Roze, J-C – sequence: 84 givenname: E surname: Saliba fullname: Saliba, E – sequence: 85 givenname: J surname: Sarlangue fullname: Sarlangue, J – sequence: 86 givenname: D surname: Semama fullname: Semama, D – sequence: 87 givenname: M surname: Walther fullname: Walther, M – sequence: 88 givenname: C H surname: Chambery fullname: Chambery, C H – sequence: 89 givenname: R surname: Berner fullname: Berner, R – sequence: 90 givenname: K surname: Harms fullname: Harms, K – sequence: 91 givenname: G surname: Horneff fullname: Horneff, G – sequence: 92 givenname: E surname: Kattner fullname: Kattner, E – sequence: 93 givenname: J surname: Liese fullname: Liese, J – sequence: 94 givenname: U surname: Lieser fullname: Lieser, U – sequence: 95 givenname: O surname: Möller fullname: Möller, O – sequence: 96 givenname: H surname: Pirmin fullname: Pirmin, H – sequence: 97 givenname: Mainz J surname: Poeschl fullname: Poeschl, Mainz J – sequence: 98 givenname: W surname: Rascher fullname: Rascher, W – sequence: 99 givenname: A surname: Rech fullname: Rech, A – sequence: 100 givenname: C surname: Rieger fullname: Rieger, C |
| CorporateAuthor | Motavizumab Study Group |
| CorporateAuthor_xml | – name: Motavizumab Study Group |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1542/peds.2008-1036 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1098-4275 |
| ExternalDocumentID | 20008423 |
| Genre | Clinical Trial, Phase III Multicenter Study Comparative Study Randomized Controlled Trial Journal Article |
| GroupedDBID | --- -ET ..I .55 .GJ 0R~ 123 18M 1CY 1HT 26- 29O 2KS 2QL 2WC 36B 39C 4.4 41~ 53G 5RE 5VS 6PF 7K8 85S 8F7 8GL 96U AAAMJ AAHTB AAIKC AAJMC AAKAS AAMNW AAQOH AAWTL AAWTO ABCZD ABIVO ABJNI ABOCM ABPEJ ABPPZ ACBMB ACGFO ACGOD ACNCT ACPRK ADCOW ADZCM AENEX AFAZI AFFNX AFHKK AFOSN AFRAH AHMBA AJUXI ALMA_UNASSIGNED_HOLDINGS BKOMP CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P F8P FEDTE GICCO GOZPB GX1 H13 HF~ HVGLF IAG IAO ICJ IEA IER IHR IMI INH INR IOF IPO IPY ISE ITC IVC KO8 KQ8 L7B LXL LXN LXY N4W N9A NEJ NPM OHT OK1 OMK OVD P0W P2P PDE PQQKQ Q.- RHI SJN TAE TEORI TR2 TWZ UBE UHB UMD W8F WH7 WHG WOQ WOW WQ9 X7M XJT XOL XZL YHG YHZ YOC YQI YQJ YZZ ZGI ZRR ZXP ~KM ~X8 7X8 |
| ID | FETCH-LOGICAL-c360t-e52c64231dde6e7abf765e1ccd6192ab49df7de7a01073d26ddaf88ff9be2b7f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 171 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000273348000034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1098-4275 |
| IngestDate | Fri Sep 05 08:40:51 EDT 2025 Mon Jul 21 05:37:32 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c360t-e52c64231dde6e7abf765e1ccd6192ab49df7de7a01073d26ddaf88ff9be2b7f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 20008423 |
| PQID | 734221410 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_734221410 pubmed_primary_20008423 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-Jan 20100101 |
| PublicationDateYYYYMMDD | 2010-01-01 |
| PublicationDate_xml | – month: 01 year: 2010 text: 2010-Jan |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Pediatrics (Evanston) |
| PublicationTitleAlternate | Pediatrics |
| PublicationYear | 2010 |
| SSID | ssj0004572 |
| Score | 2.427028 |
| Snippet | Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e35 |
| SubjectTerms | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents - therapeutic use Child, Preschool Confidence Intervals Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Infant, Premature Kaplan-Meier Estimate Male Palivizumab Primary Prevention - methods Probability Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - mortality Respiratory Syncytial Virus Infections - prevention & control Risk Assessment Survival Rate Treatment Outcome |
| Title | Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20008423 https://www.proquest.com/docview/734221410 |
| Volume | 125 |
| WOSCitedRecordID | wos000273348000034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeuoHVauI87LAghKhYWnUAqVvl-CEilaRt2gr49ZyTFFgQA0uWKLJ1uVzuuzt_HyHXEZOBslIgLJEJxfzfp8LEHuVKm1TbVDOhK7EJ3u-L4TAZNLM5ZTNWuYqJVaDWhXI18g4PQsbcUOLtZEqdaJRrrjYKGuukFWAm45yaD3-ShfO62ZkIGjIeNZyNUcg6E6Mrrm5HbRrEv2eX1V-mu_vP_e2RnSa9hLvaH_bJmskPyFavaaAfkpdeMZfL7GPxKlPAfBVwFTT0WL5lJRQWZt-ddyjfMfBiABjDMpstSshycOTG1E2jw-oQ-A1IyF1J16IrF04JDyohkCPy3H14un-kjdgCVUHszamJmEIsEvgY72LDZWp5HBlfKe0glkzDRFuu8QYCOB5oFmstrRDWJqlhKbfsmGzgcuaUQEXBr0MeWYtgxciEG8t9H4GNpzG2sjaBlQlH6MyuQyFzUyzK0ZcR2-Skfg2jSU264eQyPYH7O_v74XOyXff4XaHkgrQsfsjmkmyq5TwrZ1eVk-C1P-h9Aj8gyjk |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Motavizumab+for+prophylaxis+of+respiratory+syncytial+virus+in+high-risk+children%3A+a+noninferiority+trial&rft.jtitle=Pediatrics+%28Evanston%29&rft.au=Carbonell-Estrany%2C+Xavier&rft.au=Sim%C3%B5es%2C+Eric+A+F&rft.au=Dagan%2C+Ron&rft.au=Hall%2C+Caroline+B&rft.date=2010-01-01&rft.issn=1098-4275&rft.eissn=1098-4275&rft.volume=125&rft.issue=1&rft.spage=e35&rft_id=info:doi/10.1542%2Fpeds.2008-1036&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-4275&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-4275&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-4275&client=summon |